A universal vaccine for serogroup B meningococcus

Toscana Life Sciences · Novartis (Italy) · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

Meningitis and sepsis caused by serogroup B meningococcus are two severe diseases that still cause significant mortality. To date there is no universal vaccine that prevents these diseases. In this work, five antigens discovered by reverse vaccinology were expressed in a form suitable for large-scale manufacturing and formulated with adjuvants suitable for human use. The vaccine adjuvanted by aluminum hydroxide induced bactericidal antibodies in mice against 78% of a panel of 85 meningococcal strains representative of the global population diversity. The strain coverage could be increased to 90% and above by the addition of CpG oligonucleotides or by using MF59 as adjuvant. The vaccine has the potential to…

Citation impact

724
total citations
FWCI
30.19
Percentile
100%
References
34
Citations per year

Authors

30

Topics & keywords

Keywords
  • Reverse vaccinology
  • Meningococcal vaccine
  • Virology
  • Adjuvant
  • Meningitis
  • Population
  • Antigen
  • Medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.